Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C).
The form-1 antigen of Shigella sonnei was transferred to the avirulent Salmonella typhi strain 21a and the resulting 5076-1C transconjugate strain was tested for safety and immunogenicity as a candidate oral vaccine. The transconjugant strain was shown to be well tolerated and safe in 19 human volunteers who were fed from 1 X 10(7) to 1 X 10(10) organisms. Only two of 10 volunteers tested had developed a rise in antibody titer to the lipopolysaccharide of the hybrid 5076-1C strain.
D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology* / Q000592:standards; D003227:Conjugation, Genetic; D004405:Dysentery, Bacillary / Q000517:prevention & control; D005243:Feces / Q000382:microbiology; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D010957:Plasmids; D012485:Salmonella typhi / Q000235:genetics / Q000276:immunology*; D012764:Shigella sonnei / Q000235:genetics / Q000276:immunology*; D014435:Typhoid Fever / Q000517:prevention & control; D014436:Typhoid-Paratyphoid Vaccines / Q000276:immunology* / Q000592:standards
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; D014436:Typhoid-Paratyphoid Vaccines